ObjectiveTo compare the clinical effect of liraglutide and insulin pump in the intensive treatment of patients with type 2 diabetes mellitus. MethodsA total of 103 patients with type 2 diabetes mellitus admitted to our hospital from March 2019 to March 2020 were selected, and they were divided into observation group (52 cases) and control group (51 cases) by the random number method. The control group was given intensive insulin pump therapy (continuously subcutaneous-pumped insulin aspart injection), whereas the observation group was given liraglutide injection, with continuous treatment for 3 months. The blood glucose recovery time, and pre- and post-treatment body mass index (BMI) of the two groups were compared. The levels of fasting insulin, two-hour postprandial insulin, fasting blood glucose, two-hour postprandial blood glucose, fasting C-peptide, and two-hour postprandial C-peptide, blood uric acid, blood creatinine before and after treatment were compared between the two groups. The occurrence of hypoglycemia and major cardiovascular events during treatment were compared between the two groups. ResultsThere was no statistically significant difference between the two groups in the blood glucose recovery time (P＞0.05). Before treatment, there were no significant differences in BMI, fasting insulin, two-hour postprandial insulin, fasting blood glucose, two-hour postprandial blood glucose, fasting C-peptide, two-hour postprandial C-peptide, blood uric acid, and blood creatinine levels between the two groups (P＞0.05). After 3 months of treatment, BMI, fasting insulin, two-hour postprandial insulin, fasting blood glucose, two-hour postprandial blood glucose, blood uric acid, and blood creatinine levels of the observation group were significantly lower than those of the control group, whereas the levels of fasting C-peptide and two-hour postprandial C-peptide of the observation group were significantly higher than those of the control group, with statistically significant differences (P＜0.05). During treatment, the incidence of hypoglycemia in the observation group (3.85%) was significantly lower than that in the control group (19.61%), with a statistically significant difference (P＜0.05). There were no adverse cardiovascular events in the two groups. ConclusionCompared with intensive insulin pump therapy, liraglutide can more effectively control the BMI of patients with type 2 diabetes mellitus, improve blood glucose, insulin levels and kidney function, and decrease the incidence of hypoglycemia, with a preferable safety.

无